Which has stronger valuation & earnings, BRNS or ENGN?

enGene is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A enGene N/A N/A -$117.30M -$1.13 N/A

Is BRNS or ENGN more profitable?

enGene's return on equity of -27.97% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% enGene N/A -27.97% -22.65%

Which has higher valuation & earnings, KZIA or BRNS?

Novogen has higher revenue and earnings than Barinthus Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $1.23M 94.16 -$13.41M N/A N/A Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A

Is KZIA or BRNS more profitable?

Novogen's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Barinthus Biotherapeutics N/A -59.15% -43.80%

Which has better earnings and valuation, INO or BRNS?

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inovio Pharmaceuticals N/A N/A -$84.95M -$0.91 N/A Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A

Is INO or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Barinthus Biotherapeutics N/A -59.15% -43.80%

Barinthus Biotherapeutics (BRNS) Competitors

$0.74 0.00 (0.00%)

As of 10/9/2026

Compare

BRNS vs. ENGN, KZIA, CBUS, FHTX, and INO

Should you buy Barinthus Biotherapeutics stock or one of its competitors? Barinthus Biotherapeutics's main competitors and comparable companies include enGene (ENGN), Novogen (KZIA), Cibus (CBUS), Foghorn Therapeutics (FHTX), and Inovio Pharmaceuticals (INO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Barinthus Biotherapeutics compare to enGene?

Barinthus Biotherapeutics (NASDAQ:BRNS) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 440.47%. enGene has a consensus price target of $11.05, suggesting a potential upside of 538.47%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, enGene had 15 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 15 mentions for enGene and 0 mentions for Barinthus Biotherapeutics. enGene's average media sentiment score of 0.06 beat Barinthus Biotherapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
enGene	Neutral

Barinthus Biotherapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market. Comparatively, enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

enGene is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
enGene	N/A	N/A	-$117.30M	-$1.13	N/A

enGene's return on equity of -27.97% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
enGene	N/A	-27.97%	-22.65%

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

enGene beats Barinthus Biotherapeutics on 10 of the 13 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Novogen currently has a consensus price target of $28.80, suggesting a potential upside of 222.51%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Novogen's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

In the previous week, Novogen had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Barinthus Biotherapeutics. Novogen's average media sentiment score of 1.79 beat Barinthus Biotherapeutics' score of 0.00 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Very Positive
Barinthus Biotherapeutics	Neutral

Novogen has higher revenue and earnings than Barinthus Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$1.23M	94.16	-$13.41M	N/A	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Novogen has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market.

30.9% of Novogen shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Novogen beats Barinthus Biotherapeutics on 10 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Cibus?

Cibus (NASDAQ:CBUS) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Barinthus Biotherapeutics' return on equity of -59.15% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Cibus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market.

Cibus currently has a consensus price target of $9.00, suggesting a potential upside of 480.65%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 440.47%. Given Cibus' higher probable upside, research analysts clearly believe Cibus is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	32.55	-$127.08M	-$1.65	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

33.8% of Cibus shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cibus had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Cibus and 0 mentions for Barinthus Biotherapeutics. Cibus' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Cibus	Neutral
Barinthus Biotherapeutics	Neutral

Summary

Cibus beats Barinthus Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Foghorn Therapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Barinthus Biotherapeutics has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

Barinthus Biotherapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Barinthus Biotherapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market.

In the previous week, Foghorn Therapeutics had 11 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 11 mentions for Foghorn Therapeutics and 0 mentions for Barinthus Biotherapeutics. Foghorn Therapeutics' average media sentiment score of 0.38 beat Barinthus Biotherapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Foghorn Therapeutics	Neutral

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 440.47%. Foghorn Therapeutics has a consensus price target of $6.67, indicating a potential upside of 233.33%. Given Barinthus Biotherapeutics' higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Foghorn Therapeutics beats Barinthus Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Barinthus Biotherapeutics' return on equity of -59.15% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	N/A	N/A	-$84.95M	-$0.91	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Inovio Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market.

Inovio Pharmaceuticals presently has a consensus price target of $3.17, suggesting a potential upside of 175.36%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Inovio Pharmaceuticals had 4 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 0 mentions for Barinthus Biotherapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.76 beat Barinthus Biotherapeutics' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
Barinthus Biotherapeutics	Neutral

Summary

Inovio Pharmaceuticals beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.23M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-0.72	13.55	274.99	26.14
Price / Sales	N/A	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.41	17.17	11.22	6.33
Net Income	-$66.43M	-$22.69M	$3.50B	$382.15M
7 Day Performance	N/A	-1.34%	-0.89%	-1.40%
1 Month Performance	N/A	-8.45%	-4.42%	-3.47%
1 Year Performance	-45.58%	14.02%	7.03%	1.18%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	1.717 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
ENGN enGene	3.7459 of 5 stars	$1.75 -3.1%	$11.05 +533.0%	-80.5%	$120.63M	N/A	N/A	82
KZIA Novogen	3.5333 of 5 stars	$9.29 +0.3%	$28.80 +210.0%	+24.4%	$120.09M	$1.23M	N/A	6	Positive News
CBUS Cibus	1.6277 of 5 stars	$1.62 +3.2%	$9.00 +455.6%	+3.3%	$119.99M	$3.64M	N/A	118
FHTX Foghorn Therapeutics	2.5207 of 5 stars	$2.09 +6.1%	$6.67 +219.0%	-54.8%	$116.99M	$30.91M	N/A	106	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. ENGN, KZIA, CBUS, FHTX, and INO

How does Barinthus Biotherapeutics compare to enGene?

Summary

How does Barinthus Biotherapeutics compare to Novogen?

Summary

How does Barinthus Biotherapeutics compare to Cibus?

Summary

How does Barinthus Biotherapeutics compare to Foghorn Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. ENGN, KZIA, CBUS, FHTX, and INO

How does Barinthus Biotherapeutics compare to enGene?

Do analysts rate BRNS or ENGN?

Does the media prefer BRNS or ENGN?

Which has more volatility & risk, BRNS or ENGN?

Which has stronger valuation & earnings, BRNS or ENGN?

Is BRNS or ENGN more profitable?

Do institutionals & insiders hold more shares of BRNS or ENGN?

Summary

How does Barinthus Biotherapeutics compare to Novogen?

Do analysts rate KZIA or BRNS?

Is KZIA or BRNS more profitable?

Does the media favor KZIA or BRNS?

Which has higher valuation & earnings, KZIA or BRNS?

Which has more risk & volatility, KZIA or BRNS?

Do insiders and institutionals hold more shares of KZIA or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Cibus?

Is CBUS or BRNS more profitable?

Which has more volatility & risk, CBUS or BRNS?

Do analysts rate CBUS or BRNS?

Which has better earnings & valuation, CBUS or BRNS?

Do institutionals & insiders hold more shares of CBUS or BRNS?

Does the media prefer CBUS or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Foghorn Therapeutics?

Which has higher valuation & earnings, BRNS or FHTX?

Is BRNS or FHTX more profitable?

Which has more volatility and risk, BRNS or FHTX?

Does the media prefer BRNS or FHTX?

Do analysts rate BRNS or FHTX?

Do institutionals & insiders have more ownership in BRNS or FHTX?

Summary

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Do insiders and institutionals have more ownership in INO or BRNS?

Is INO or BRNS more profitable?

Which has better earnings and valuation, INO or BRNS?

Which has more risk and volatility, INO or BRNS?

Do analysts recommend INO or BRNS?

Does the media prefer INO or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools